Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Corporate Presentation
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Press Releases

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • 2025 AGM
  • Corporate Presentation
    • Corporate Presentation
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Overview
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News & Events

  • Press Releases
  • IR Calendar
  • 2025 AGM
November 13, 2019 • 4:05 pm EST

Aurinia Announces Updates to the Board of Directors

November 7, 2019 • 6:30 am EST

Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil

November 6, 2019 • 4:05 pm EST

Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019

October 31, 2019 • 6:30 am EDT

Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome

October 16, 2019 • 6:30 am EDT

Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility

September 26, 2019 • 4:05 pm EDT

Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

September 13, 2019 • 5:11 pm EDT

Aurinia Establishes At-the-Market Facility

September 6, 2019 • 6:05 am EDT

Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

August 6, 2019 • 4:02 pm EDT

Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights

August 1, 2019 • 6:30 am EDT

Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.